Clinical Trial: Real-world Efficacy and Safety of Neoadjuvant Dostarlimab in Patients With dMMR/MSI-H Locally Advanced Rectal Cancer

U.S., Dec. 9 -- ClinicalTrials.gov registry received information related to the study (NCT07269249) titled 'Real-world Efficacy and Safety of Neoadjuvant Dostarlimab in Patients With dMMR/MSI-H Locally Advanced Rectal Cancer' on Nov. 25.

Brief Summary: This is an observational, retrospective-prospective, multicentre trial enrolling all patients included in the AIFA monitoring registry of Dostarlimab for the indication in rectal cancer. The aims of the study are to describe the clinical outcomes and safety of patients with dMMR/MSI-H locally advanced rectal cancer (LARC) receiving neoadjuvant dostarlimab in the real-world setting.

Study Start Date: Sept. 01

Study Type: OBSERVATIONAL

Condition: Locally Advanced Rectal Cancer (LARC)

Inte...